LYMPHVECs
Financiado
Development of lipid nanoparticles based on solid matrix for Benznidazole oral d...
Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to the lymphatic system to treat Chagas disease
According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. CD is one of the most significant health problems of Latin America. However, nowadays it ha...
According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. CD is one of the most significant health problems of Latin America. However, nowadays it has been reported worldwide. Benznidazole (BZ) has been recently approved in US (30/08/2017) as the first option treatment for CD but can only administered for 14 days or less, while it is known that at least 2-3 months of treatment are required for full efficacy. This approval for short-term CD therapy is due to the severe side effects associated with extended use, which severely impacts the applicability of BZ as a universal CD treatment.
Importantly, Trypanosoma cruzi (Tc) parasite reservoirs have been localized into the Lymphatic System (LS). Poor compound distribution into the LS could be the reason why extended BZ treatment is required and why reactivation of the parasites in the chronic stage is commonly found.
Chagas infected people treated with BZ develop rashes, fever, nausea, headache, allergic dermatitis, digestive intolerance (anorexia), peripheral neuropathy and insomnia. These severe side effects limit its use and foster non-compliance. BZ formulations that reduce compound exposure in system circulation while facilitating distribution into the LS could reduce the efficacious dose (at present 5-7mg/kg/day), reduce side effects, and possibly contribute treatment shortening. This project will develop BZ formulations based on solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to achieve these three goals.
ver más
Duración del proyecto: 35 meses
Fecha Inicio: 2018-04-12
Fecha Fin: 2021-03-31
Fecha Fin: 2021-03-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-03-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2017:
Individual Fellowships
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
158K€
Líder del proyecto
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO
Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica
Perfil tecnológico
TRL
4-5
130K
Perfil tecnológico
TRL
4-5
130K